Our Science – Mitsuya Website
Hiroaki Mitsuya, M.D., Ph.D.
Development of Therapeutics for HIV Infection and AIDS
In the therapy of HIV infection and AIDS, we have lately seen what is called cautious optimism. It is now evident that antiviral intervention brings about clinical benefits in both symptomatic and asymptomatic patients with HIV infection and that protease inhibitors (PIs) or nonnucleoside reverse transcriptase inhibitors (NNRTIs) administered with nucleoside reverse transcriptase inhibitors (NRTIs) block HIV replication more profoundly and persistently than ever.
This significant progress was possible mainly with combination chemotherapy using NRTIs with PIs or NNRTIs (highly active antiretroviral therapy or HAART). In 1985, utilizing an in vitro drug testing system involving human target cells Dr. Mitsuya created by himself, Dr. Mitsuya showed for the first time that AZT had potent anti-HIV activity in vitro. Based on such data, AZT was ultimately selected for the clinical trial at the NCI and he collaborated in a series of clinical studies, establishing AZT as the first drug for AIDS therapy. Concomitantly, Dr. Mitsuya discovered that 2',3'-dideoxynucleosides (ddNs) were active as a 'family' against HIV. Of these, ddI and ddC ultimately came into clinical use as important anti-HIV drugs. Dr. Mitsuya also showed that ddNs served as substrates for HIV reverse transcriptase, which upon interaction with the latter undergoes viral DNA chain termination, and the ddNs become active against a number of human retroviruses under certain conditions, thus establishing the general conditions for the antiretroviral effect of ddNs.
Since these epochal studies, Dr. Mitsuya has continued to produce important insights into the therapy of AIDS. In 1990s, Dr. Mitsuya showed for the first time that NRTIs can be classified into two groups: (i) cell-activation-dependent ddNs such as AZT and 2',3'dideoxy-2',3'-didehydrothymidine (d4T) that are preferentially phosphorylated, yield higher ratios of ddN 5'-triphosphate (ddNTP)/2'-deoxynucleoside 5'-triphosphate (dNTP), and exert more potent anti-HIV activity in activated cells than in resting cells; and (ii) cell-activation-independent NRTIs including ddI, and ddC that produce higher ratios of ddNTP/dNTP and exert more potent activity against the virus in resting cells. These findings have provided the basis for the design of currently available combination chemotherapy with NRTIs.
Another major focus of Dr. Mitsuya's research is the drug-resistant HIV problem. In 1992, Dr. Mitsuya showed that HIV develops resistance to AZT more readily than ddI and ddC and that HIV develops a set of novel mutations, which confer multidrug resistance (MDR) on HIV. Dr. Mitsuya and his group have continued and extended the study of MDR HIV variants. In response to the drug-resistant HIV problems and in collaboration with intramural and extramural scientists, Dr. Mitsuya's group has identified several promising protease inhibitors (PIs), which are extremely potent against wild-type HIV and HIV variants resistant to various PIs. One such PI is darunavir (DRV/TMC-114/Prezista), which was designed, synthesized and identified in collaboration with Professor Arun K. Ghosh of Purdue University.
DRV, unlike other PIs, binds to the main chains of the protease active site amino acids, a unique property, presumably enabling DRV to be active against multi-PI-resistant HIV variants. Most recently, Dr. Mitsuya and his group discovered that DRV and its related compounds strongly block the dimerization process of HIV protease, an essential process for HIV replication, using the FRET-based HIV expression system Dr. Mitsuya's group generated. Indeed, DRV, used with other drugs in combination, has been significantly benefiting a number of patients harboring multi-drug resistant HIV variants, whose clinical conditions would have been otherwise acutely deteriorating. DRV appears to have embodied a breakthrough in the struggle against the notorious obstacle of current AIDS therapy: multi-drug-resistant HIV variants. The dual antiviral function of DRV, inhibiting protease subunit dimerization as well as protease enzymatic activity, appears to explain why DRV is such a highly effective anti-AIDS therapeutic and differentiates itself from many of other 'conventional' PIs. The development of DRV, the fourth AIDS drug developed at the NCI, was selected as one of the top two advances by the NCI in 2007 and this advance was sent to HHS for inclusion in the 'Major Accomplishments by the NIH-2008'.
Dr. Mitsuya is also developing a unique NRTI, 4-ethynil-2-fluoro-2-deoxyadenosine (EFdA), which exerts highly potent antiviral activity against HIV-1, HIV-2, and simian immunodeficiency virus (SIV) with IC50 values of subnanomolar concentrations or lower. EFdA has been shown to potently suppress SIV replication and increase CD4 T-cell counts in SIV-infected monkeys, in collaboration with Professor Michael Parniak of Pittsburgh University.
Dr. Mitsuya and his group have a wide range of scientific and practical interests in a number of modalities of antiretroviral intervention and both national and international active collaborations are always in progress.
Those Dr. Mitsuya has been actively in collaboration with include: Arun Ghosh, Purdue University; Robert Yarchoan and Victor Marquez, NCI, NIH; Edward Arnold, Rutgers University; Shinichi Oka, International Medical Center, Tokyo; Seiji Okada, Kumamoto University, Japan; Stefan Sarafianos, University of Missouri; Ladislau Kovari, Wayne State University; Hiroyuki Hayakawa, Yamasa Co., Japan; and Jiri Zemlicka, Karmanos Cancer Institute.
This page was last updated on 2/21/2013.